首页> 外文期刊>American Journal of Cardiovascular Disease >Does albuminuria predict renal risk and/or cardiovascular risk in obese type 2 diabetic patients?
【24h】

Does albuminuria predict renal risk and/or cardiovascular risk in obese type 2 diabetic patients?

机译:蛋白尿是否可以预测肥胖的2型糖尿病患者的肾脏风险和/或心血管风险?

获取原文
       

摘要

Increased urinary albumin excretion (UAE) is a marker of renal and cardiovascular risk in patients with type 2 diabetes (DT2). What about the obese patient with DT2? Does albuminuria predict the progression of renal disease and/or cardiovascular disease? The objective of this study is to determine the link between albuminuria, renal risk and cardiovascular risk in a cohort of obese DT2 patients. This is a prospective study begun in September 2006. It included DT2 patients presenting obesity defined by a body mass index (BMI)>30 Kg/msup2/sup. Three groups of patients were defined: normo-albuminuria (Urinary Albumin Excretion UAE<30 mg/day or Albumin Creatinine Ratio ACR<30 mg/g), micro-albuminuria (UAE=30-300 mg/day or ACR=30-300 mg/g) and macro-albuminuria (UAE>300 mg/day or ACR>300 mg/g). Data on 144 obese DT2 patients were compiled: The mean age of our patients was 59 ± 9 years and the sex ratio 0.26. The incidence of ESRD was higher in the macro-albuminuria group than in the two other groups (26.5% vs. 1.2%, p<0.001). The incidence of cardiovascular events was 15.4%, 14.3% and 23.5% in the normo, micro and macro-albuminuria groups (p=0.48). A history of cardiovascular comorbidities was the main cardiovascular risk in multivariate analysis (0R=15.07; 95% CI=5.30-42.82; p<0.001) and the low admission GFR (0R=5.67; 95% CI=1.23-9.77; p=0.008) was the main factor for progression of kidney disease in multivariate analysis. Albuminuria may be a better marker of kidney disease progression than of cardiovascular risk in the obese DT2 patient, according to our results. However, to accurately demonstrate the link albuminuria - renal risk and albuminuria - cardiovascular risk in the obese DT2 patient, additional studies using very strict criteria of selection and judgment are needed.
机译:尿白蛋白排泄(UAE)增加是2型糖尿病(DT2)患者肾和心血管风险的标志。肥胖的DT2患者呢?蛋白尿是否可以预测肾脏疾病和/或心血管疾病的进展?这项研究的目的是确定一群肥胖的DT2患者的白蛋白尿,肾脏风险和心血管风险之间的联系。这是一项始于2006年9月的前瞻性研究,研究对象是由肥胖指数(BMI)> 30 Kg / m 2 定义的DT2肥胖症患者。定义了三组患者:正常白蛋白尿(尿白蛋白排泄量UAE< 30 mg /天或白蛋白肌酐比值ACR< 30 mg / g),微量白蛋白尿(UAE = 30-300 mg / day或ACR = 30-300 mg / g)和大量白蛋白尿(UAE 300 mg /天或ACR 300 mg / g)。收集了144例肥胖DT2患者的数据:我们患者的平均年龄为59岁。 9岁,性别比0.26。大白蛋白尿组的ESRD发生率高于其他两组(26.5%vs. 1.2%,p< 0.001)。在正常,微量和大量白蛋白尿组中,心血管事件的发生率分别为15.4%,14.3%和23.5%(p = 0.48)。心血管合并症的病史是多变量分析中的主要心血管风险(0R = 15.07; 95%CI = 5.30-42.82; p< 0.001)和低入院GFR(0R = 5.67; 95%CI = 1.23-9.77; p = 0.008)是多变量分析中肾脏疾病进展的主要因素。根据我们的结果,在肥胖的DT2患者中,蛋白尿可能是比心血管疾病风险更好的肾脏疾病进展指标。但是,为了准确显示肥胖DT2患者的蛋白尿-肾脏风险和蛋白尿-心血管风险之间的联系,需要使用非常严格的选择和判断标准进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号